Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for the treatment of acute myeloid leukemia

A therapeutic composition, active ingredient technology, applied in the field of molecular medicine, capable of addressing issues such as new treatments for AML without insights, specific genes or microRNAs that have not yet been identified

Inactive Publication Date: 2012-04-18
ERASMUS UNIV MEDICAL CENT ROTTERDAM ERASMUS MC
View PDF0 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0015] Although these and other studies have provided important information for the diagnosis of AML, they have not provided insights into new therapies for AML because it has not been determined whether overexpression or underexpression of specific genes or microRNAs is an epiphenomenon of disease pathogenesis or a cause of it

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for the treatment of acute myeloid leukemia
  • Method for the treatment of acute myeloid leukemia
  • Method for the treatment of acute myeloid leukemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0030] We found that microRNA-9 / 9* plays a role in leukemic transformation in acute myeloid leukemia AML.

[0031] When used herein, the term miRNA 9 / 9* is intended to refer to microRNA 9 and / or microRNA 9*.

[0032]MicroRNAs are single-stranded RNAs of 18-25 nucleotides and are produced from precursor molecules. microRNAs are encoded in the genome and transcribed by RNA polymerase II into primary transcripts called pri-microRNAs, which are processed in the nucleus into one or more pre-microRNAs by nuclear RNase III Drosha and the double-stranded RNA-binding protein Pasha / DGCR8 microRNA (pre-microRNA) (32, 33). In the cytoplasm, another RNaseIII called Dicer further processes the pre-microRNA into a double-stranded, 23-nucleotide mature microRNA. This microRNA duplex (34) comprises a strand incorporated into the RNA-induced silencing complex (RISC) (microRNA strand) and a complementary strand (microRNA* strand), which is normally degraded.

[0033] There are several excepti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention is in the field of molecular medicine and provides methods for the treatment of acute myeloid leukemia. These methods are based on the observation that microRNA-9 and microRNA-9* are involved in the pathogenesis of the disease in that the overexpression of microRNA-9 / 9* block myeloid differentiation in vitro. More in particular, microRNA-9 / 9* were found to play a role in leukemic transformation in acute myeloid leukemia.

Description

field of invention [0001] The invention belongs to the field of molecular medicine and provides a method for treating acute myelogenous leukemia. These approaches are based on the observation that microRNA-9 and / or microRNA-9* (microRNA-9 / 9*) are involved in the pathogenesis of the disease, since overexpression of microRNA-9 / 9* blocks myeloid differentiation in vitro. More specifically, microRNA-9 / 9* was found to play a role in leukemic transformation in acute myeloid leukemia. Background of the invention [0002] Acute myelogenous leukemia (AML) is a remarkably heterogeneous malignancy disease characterized by uncontrolled clonal proliferation of hematopoietic progenitor cells blocked at different developmental stages. The altered clinical biology and prognosis are mainly driven by somatic genetic aberrations such as t(15;17), t(8;21), inv(16), 11q23, 3q26 aberrations and monochromosomal karyotypes (1-3) as well as various determined by a genetic mutation. Prominent exam...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/11A61K31/7088A61P35/02
CPCC12N2320/11C12N15/113C12Q2600/158C12Q1/6886C12N2330/10C12N2310/141A61P35/02C12N15/11A61K31/7088A61K48/00A61K31/7105
Inventor 鲍伯·洛温伯格莫耶卡·拉夫伦契奇彼得·雅各布斯·马里亚·瓦尔克孙旭明
Owner ERASMUS UNIV MEDICAL CENT ROTTERDAM ERASMUS MC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com